Loading company…
Metagenomi develops gene-editing systems and cell and gene therapies for genetic diseases.
Founded in 2018 in California, Metagenomi develops CRISPR-based systems for researching and treating genetic diseases, including cystic fibrosis, sickle-cell anemia, and Marfan syndrome. The company was founded by Brian Thomas and Jillian Banfield. In February 2024, it raised USD 93.75 million in an IPO, selling 6.25 million shares at USD 15 per share on the Nasdaq Global Select Market under ticker MGX.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in